Veraxa Biotech is trading 5.31% lower at $1.07, with no confirmed company-specific reason identified. - Its investor-relations releases page lists October 13 as the latest release; the October 29 after-hours catalyst was reported as unclear. - The supplied market context shows the S&P 500 down 1.00% and Nasdaq down 2.19%. - Broader risk-off trading may be contributing, but available evidence does not establish a direct company-specific cause.